Projects Wirth

 

Sie befinden sich hier:

Project description

As shown in other entities, the ductal adenocarcinoma of the pancreas is characterized by molecular subtypes that could be exploited therapeutically. Based on this knowledge, we try to develop new therapeutic options. By high-throughput drug-screen experiments we aim to improve efficacy of known drugs by additionally targeting specific molecular nodes in certain tumor subtypes. Both pharmacological and genetic inhibition of such nodes are subsequently analyzed in detail to dissect the molecular mechanisms and identify the mode of action.

Selected publications

  • Hassan Z, Schneeweis C, Wirth M, Veltkamp C, Dantes Z, Feuerecker B, Ceyhan GO, Knauer SK, Weichert W, Schmid RM, Stauber R, Arlt A, Krämer OH, Rad R, Reichert M, Saur D, Schneider G. MTOR inhibitor-based combination therapies for pancreatic cancer. Br J Cancer. 2018 Feb 6;118(3):366-377
  • Stojanovic N #, Hassan Z #, Wirth M #, Wenzel P, Beyer M, Schäfer C, Brand P, Kroemer A, Stauber RH, Schmid RM, Arlt A, Sellmer A, Mahboobi S, Rad R, Reichert M, Saur D, Krämer OH, Schneider G. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Oncogene. 2017 Mar 30;36(13):1804-1815. (# contributed equally)
  • Diersch S #, Wirth M #, Schneeweis C #, Jörs S, Geisler F, Siveke JT, Rad R, Schmid RM, Saur D, Rustgi AK, Reichert M, Schneider G. Kras (G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells. Oncogene. 2016 Jul 21;35(29):3880-6. (# contributed equally)
  • Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sánchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, Trajkovic-Arsic M, Gupta A, Heid I, Noël PB, Braren R, Erkan M, Kleeff J, Sipos B, Sayles LC, Heikenwalder M, Heßmann E, Ellenrieder V, Esposito I, Jacks T, Bradner JE, Khatri P, Sweet-Cordero EA, Attardi LD, Schmid RM, Schneider G, Sage J, Siveke JT. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med. 2015 Oct;21(10):1163-71.
  • Wirth M, Stojanovic N, Christian J, Paul MC, Stauber RH, Schmid RM, Häcker G, Krämer OH, Saur D, Schneider G. MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib. Nucleic Acids Res. 2014;42(16):10433-47.

Funding sources

  • Else Kröner-Fresenius-Stiftung
  • Walter Schulz Stiftung